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Abstract
Background: Patients’ understanding of their condition affect the choice of treatment. The aim of this study is to
evaluate patients’ understanding and treatment preferences before and after an information session on the
treatment of acute optic neuritis.
Methods: Participants were asked to complete a questionnaire consisting of 14 questions before and after an
information session presented by a neuro-ophthalmologist. The information session highlighted the treatment
options and the treatment effects based on the Optic Neuritis Treatment Trial in plain patient language. The
information session stressed the finding that high dose intravenous steroid therapy accelerated visual recovery but
does not change final vision and that treatment with oral prednisone alone resulted in a higher incidence of
recurrent optic neuritis.
Results: Before the information session, 23 (85%) participants knew that there was treatment available for ON and
this increased to 27 (100%) after the information session. There were no significantly change in patients knowledge
of symptoms of ON and purpose of treatment before and after the information session. Before the information
session, 4 (14%) respondents reported they would like to be treated by oral steroid alone in the event of an optic
neuritis and 5 (19%) did not respond. After the education session, only 1 patient (4%) indicated they would
undergo treatment with oral steroid alone but 25 (92%) indicated they would undergo treatment with intravenous
steroid treatment, alone or in combination with oral treatment. Results indicated that there were significant
differences in the numbers of participants selecting that they would undergo treatment with a steroid injection
(n = 22, p = 0.016).
Conclusions: In this study, patients have shown good understanding of the symptoms and signs of optic neuritis.
The finding that significant increases in the likelihood of patients engaging in best practice can be achieved with
an information session is very important. This suggests that patient knowledge of available treatments and
outcomes can play an important role in implementing and adopting guideline recommendations.
Background
Integrating evidenced based practice into daily clinical
care of patients is the driving force behind much needed
clinical research. It is commonly assumed that clinical
evidence ultimately transforms clinical management by
health professionals and results in better patient out-
comes. Recently it has been highlighted that evaluation
of the impact of major clinical trials “Translational T2
Clinical Research” is essential when assessing the effects
of interventions designed to improve quality of care
[1,2]. Although such translational research is important
to implement change, there are other barriers to change
that may occur at the level of the patient, the clinician
or the healthcare system [1,3].
Patient preferences in adopting the best practice for
their own management is not known. Making evidence
based decisions is a complex process integrating evi-
dence based information with patient’s circumstances
and the individual patient’s preferences [4-6]. Surveying
patient understanding of their condition, their choice of
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treatment and barriers to treatment options is important
to implement best practice.
Optic neuritis (ON) is an acute inflammation of the
optic nerve resulting in painful loss of vision. Optic
neuritis may be a clinically isolated syndrome but it can
also be associated with Multiple Sclerosis (MS) which is
a systemic demyelinating condition. In about a quarter
of MS cases, the patient first presents with optic neuritis
and over half of MS patients have at least one episode
of optic neuritis during the course of their condition
[7,8]. There is Level 1 evidence obtained from at least
one properly designed randomized controlled trial [9]
that treatment of an acute optic neuritis with intrave-
nous corticosteroid followed by oral steroid results in
faster vision recovery [10-12]. Optic neuritis is an ideal
model to investigate patient understanding and belief as
the signs and symptoms of optic neurits can be readily
identified; the natural history of the condition and the
effect of treatment with intravenous steroid have been
studied [8,10,13]. Treatment with intravenous corticos-
teroid can help with faster vision recovery but does not
change the final vision. As optic neuritis is a prominent
feature of MS, which is a chronic condition that affects
young people in the most productive years of their lives,
and understanding patient preferences is essential to
ensure good chronic disease management.
The aim of this study is to evaluate patient under-
standing and preferences regarding the treatment of
acute optic neuritis and to determine whether a patient
information session can assist in increasing the likeli-
hood that patients will engage in guideline recom-
mended best practice management.
Methods
Patients newly enrolled with the Multiple Sclerosis
Society of South Australia and Northern Territory from
1 November 2008 to 31 April 2009 were invited to a
“Newly Diagnosed Multiple Sclerosis Information Eve-
ning”. The society is a not for profit organization that
provides a range of services including education and
support for people who are newly diagnosed, and their
families. The Newly Diagnosed Information Session is
an education and support seminar which is organized
twice a year and is tailored specifically to the person
within 12 months of diagnosis of MS. The information
session was developed in response to their clients’
requests for information. It has been running for over
10 years. The current format of two invited guest speak-
ers of the clients’ choices (e.g. a neurologist, a phy-
siotherapist, an ophthalmologist, a counsellor), followed
by a panel discussion. During panel discussion time,
participants can write down their questions or ask
directly. This is facilitated by the senior MS Counsellor
who has been running the session and found the process
encourage participants to voice their questions.
Sixty newly diagnosed patients were registered with
the organization and were invited to attend the informa-
tion session. Prior to the session, participants were
mailed a letter informing them of the study to under-
stand participants’ views on optic neuritis. Thirty people
attended the session. At the start of the session, partici-
pants were invited to participate in a survey that com-
prised a questionnaire before and after an information
session. Participation was entirely voluntary and this was
clearly expressed to the participants on the front page of
the Participant Information Sheet and Consent Form.
The study was approved by the Flinders Clinical
Research Ethics Committee.
Those who consented were given a survey of 14 ques-
tions on the diagnosis and treatment of acute optic
neuritis (Additional File 1). The questionnaires were
self-administered and for each question participants
were given a list of responses to choose from. In several
categories, respondents were allowed to select more
than one response. Data was collected from each
respondent, on the same variables before and after the
information session. Data from before and after were
linked by a unique identifying number on participant
response forms. For each question, responses were tal-
lied and presented as percentages of respondents who
selected each option.
The information session consisted of a Powerpoint
presentation presented by a neuro-ophthalmologist for
35 minutes. The content of the presentation included
information about symptoms and signs of optic neuritis,
and the treatment options available based on the Optic
Neuritis Treatment Trial (ONTT) [14-16]. The pros and
cons of different treatment options and the adverse
effects of treatment were discussed. The natural history
of optic neuritis recovery if the person did not receive
any treatment were presented, outlining that non-treat-
ment is an option. The information session highlighted
that high dose intravenous steroid therapy accelerated
visual recovery but did not change the long-term visual
outcome. The findings that treatment with low dose
oral prednisone alone had a significantly higher inci-
dence of recurrent optic neuritis in the same or fellow
eye were highlighted. There was a second Powerpoint
presentation by a neurologist concentrating on immuno-
modulator therapy for 35 mintues. A short break of 20
mintues was taken for refreshments. During this time, a
box is provided by the MS counsellor encouraging peo-
ple to write down any questions they have. The presen-
tation was followed by a panel discussion of 30 minutes
with the neuro-ophthalmologist, the neurologist, an MS
specialist nurse and counsellor, a physiotherapist, a
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social worker and an occupational therapist to answer
any questions raised by the patients.
The guideline recommendation for treatment of acute
optic neuritis includes no treatment or treatment with
intravenous steroid injection [12]. Low dose oral treat-
ment is not a guideline recommended management.
The researchers predicted that attending an information
session would increase the likelihood that a person with
optic neuritis will be inclined to engage in guideline
recommended treatment. In order to test this hypoth-
esis, McNemar chi-squared tests were performed on
before and after data relating specifically to these vari-
ables. Respondents with missing data were excluded
from the corresponding analysis. Using Bonferroni’s cor-
rection method to control for multiple tests, a p-value
of less than 0.025 was considered significant.
Results
A total of 27 participants completed the survey before
and after the education session. The overall response
rate was 90%. The majority of participants were aged
between 31-60 years of age, with 11 (41%) of the study
population in the 31 to 45 age group (Table 1).
All participants were within 4-8 months of MS diag-
nosis. Of the participants surveyed, 19 (70%) had heard
of the term optic neuritis before the information session
and about half had optic neuritis in the past.
Participants had a good understanding of the symp-
toms associated with optic neuritis before the informa-
tion session identifying blurred vision and pain with
eye movement as the salient features of optic neuritis
(Figure 1).
Table 2 shows participant understanding of various
aspects of optic neuritis treatment before and after the
information session. Before the information session, 23
(85%) participants knew that there was treatment avail-
able for ON and 2 people (7%) did not think there were
treatments available. Two people (7%) did not respond.
After the information session, all participants (100%)
knew that there are treatments available.
Participants were asked to choose which treatment
options they would undergo in the event of an optic
neuritis episode. Before the information session, 4 (14%)
respondents reported they would elect to be treated by
oral steroid alone in the event of an optic neuritis and
5 (19%) did not indicate how they would like to be trea-
ted. Fifteen (56%) indicated they would have intravenous
treatment. After the education session, only 1 patient
(4%) indicated they would undergo treatment with oral
steroid alone. Twenty-five (92%) indicated they would
undergo treatment with intravenous steroid treatment,
either alone or in combination with oral treatment. One
patient (4%) indicated they would do nothing in the
event of acute optic neuritis. Results indicated that there
were significant differences in the numbers of partici-
pants selecting that they would undergo treatment with
a steroid injection (n = 22, p = 0.016).
Initially, only 10 (37%) participants believed that treat-
ment is most effective if administered within 1 week of
optic neuritis symptom onset. This increased to 19
(70%) after the information session. Results of the
McNemar chi-square indicate that this was not signifi-
cant (n = 25, p = 0.08).
In response to the purpose of treatment, most partici-
pants recognized that treatment makes vision recover
faster and this was selected by 17 (63%) participants
before the information session and increased to 23
(85%) after the information session. Before the informa-
tion session, 5 (18%) respondents chose, “Don’t know”
as the response to purpose of treatment but this was
reduced to zero after the information session. Of the
choices given (Table 2), the choice, “Make vision recover
to normal” is an incorrect belief. Before the information
session, 7 (26%) chose the answer and 6 (22%) partici-
pants continue to believe so after the information
session.
Discussion
Increasing patient understanding of guideline recom-
mended best practice is important in management of
chronic medical conditions such as MS. This approach
has the advantage of better patient compliance, greater
satisfaction with the health care provider/patient inter-
action and this translates into an increase in the quality
adjusted life years experienced by an MS sufferer.
Awareness of the management options and rationales
will result in increased adherence to guideline recom-
mendations. Although there is some concern that pro-
viding evidenced based information to patients may
increase their anxiety and distress, numerous studies in
MS patients found no adverse emotional effects on
patients [17,18]. It has also been shown that communi-
cating with patients about medical evidence increases
their knowledge regardless of the communication tools
used [19].
In this study, more than half of the people with newly
diagnosed MS had heard of the term optic neuritis
before the information session and more than half
reported previous optic neuritis. This highlights the high
Table 1 Participants’ demographics
Age: Number (n = 27) Percentage
15 - 30 5 18
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prevalence of optic neuritis as a presenting or relapsing
feature in people with MS. Our study may have been
biased in terms of the results of prior knowledge of
optic neuritis given the high proportion of patients with
previous optic neuritis. Hence there were no significant
differences in symptom recognition after the informa-
tion session. The treatment options emerged as key fea-
tures from this survey that has important management
implications. After the information session, more parti-
cipants elect to be treated with intravenous corticoster-
oids as the preferred treatment option compared to
before the information session. A significant number
elect to be treated early after recognizing the symptoms
of optic neuritis.
The information session highlighted the findings of
the ONTT that showed oral corticosteroid increases the
rate of relapse in the same or fellow eye by about 30%.
Therefore, low dose oral steroid alone is not a recom-
mended guideline management option. There was a
reduction of patients who indicated they would want to
be treated with oral steroid alone after the information
session (14% to 4%). More importantly, all participants
have chosen a management option after the information
session (19% did not before the information session).
Despite previous publications citing that treatment of
oral steroid alone is not an evidenced based recom-
mended practice, a survey of the preference of optic
neuritis treatment amongst Australian and New Zealand
ophthalmologists and neurologists, showed that about
20% of both ophthalmologists and neurologists were still
prescribing low dose oral corticosteroids [3]. Similarly,
in an international survey on the management of optic
neuritis, low dose oral steroid of 1 mg/km/day was still
the recommended treatment of up to 65% of neurologist
and 45.5% of ophthalmologist [1]. There is a significant
variability between countries and depending on if the
physician is an ophthalmologist or a neurologist. Those
who chose oral steroid alone as a treatment option
before the information session may have received this as
a prior treatment for their optic neuritis. Reassuringly,
after the information session, less people indicate they
would undergo the option of oral steroid alone. How-
ever, one participant continued to select this option and
it is important to explore the potential reasons for this.
Patients could have different views and interpretations
of a treatment options. Appraisal of treatment effects
may be counterbalanced by side effects and personal
inconveniences governing the individual’s final decision
on treatment preference. If the reason for not taking up
intravenous treatment is due to concern, such as a nee-
dle-phobia or fear of having to go into a hospital, then
patient information regarding alternative options for
“out of hospital” management such as a day suite or
“Hospital at Home” services for the infusion, or reinfor-
cement of the option of non-treatment, may help
patients to adopt the best practice.
Figure 1 Patient understanding of Optic Neuritis symptoms before and after the education session. Figure shows percentage of
participant responses to five ocular symptoms. There was no significant change in responses before and after the education session.
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In this study, approximately a quarter of participants
believed that treatment with corticosteroids improved
their final visual outcome. This is in conflict with the
ONTT findings presented which clearly emphasized that
corticosteroids accelerate visual recovery but do not
reduce long term recurrence. There is a significant step
between information provided by the clinician and that
interpreted by the patients. The information and patient
education should not be offered solely on the basis of
what professionals believe to be necessary for the patient
to know, but also on the basis of what patients want to
know. The patients’ actual worries and uncertainties
should be taken as a basis for providing information and
answers. In optic neuritis, re-gaining vision is a genuine
concern for the patient affected and hence may affect
the person’s adaptation of what they’d like to believe. In
promoting patient self care management, the health care
professional has an explicit educational role, as well as a
monitoring role [20] to ensure not just information is
provided, but that information is correctly interpreted.
Trobe et al showed that 65% of neurologists and 45% of
ophthalmologists also believed that steroids improve
final visual outcome [21]. It is therefore not uncommon
for both patients and clinicians to hold views different
to those supported by the evidence from major clinical
trials. In implementation of best evidenced-based prac-
tice, awareness and agreement need to come about
before adoption and adherence [22].
This study highlights that patients’ preferences play an
integral role in their management. Chong et al. noted
that current high quality clinical practice guidelines have
not given sufficient weighting to patient preferences [23]
and this may have accounted for barriers to implement-
ing evidence based recommendations in clinical settings
[24]. Chong et al. identified several barriers in integrat-
ing patient preferences into clinical guidelines. A key
enabler in guideline uptake will be to recognize and
include preference evidences. Omitting patients’ prefer-
ence excludes an important element of what constitutes
“best practice” to a patient.
Patient information is an integral part of best practice.
Ennis et al. noted that in chronic disease such as MS,
patients are not scared by information about their con-
dition but in contrast, are able to digest complex medi-
cal information [25]. Having the information accessible
to the patient with relevant information programs cater-
ing for the patient is therefore an important step for-
ward to implementing best guideline recommended
practices.
The study has several limitations including the self
reporting bias introduced with survey methodology. The
target population of this survey were people with newly
diagnosed MS; their responses were likely influenced by
their first clinical experience and the treatment given.
Therefore, the results may be less applicable to more
experienced MS patients. Another possible limitation of
the study is that only the most highly motivated patients
attended the session hence raising the question of the
generalizability of the study. In our study, the majority
of the attendees have a good understanding of the
symptoms of optic neuritis prior to the information ses-
sion and hence no significant change in knowledge of
the disease is seen before and after the information ses-
sion. However, this remains an important issue even if it
only concerns newly diagnosed highly motivated
patients. A further limitation of the study is that the
information session did not address uncertainties asso-
ciated with the ONTT which may influence patients’
preferences to treatment options.
Conclusions
In this study, patients have shown good understanding
of the symptoms and signs of optic neuritis. The finding
that significant increases in the likelihood of patients
Table 2 Participants’ understanding of Optic Neuritis




Do you think there is treatment available?
Yes 23 (86%) 27 (100%)
No 2 (7%) 0
Non Responders 2 (7%) 0
Which option would you undergo? (choose one option)
Do nothing 3 (11%) 1 (4%)
Oral steroid Tablets alone 4 (14%) 1 (4%)
Steroid Injection 15 (56%) 25 (92%)
Non Responders 5 (19%) 0
When is treatment most effective from onset of symptoms? (choose
one option)
Within 1 week 10 (37%) 19 (70%)
Within 2 weeks 1 (4%) 1 (4%)
Within 1 month 1 (4%) (4%)
Within 3 months 4 (14%) 2 (7%)
Always effective 4 (15%) 4 (15%)




What are the purposes of treatment? (may choose more than one
option)
Reduce further attacks 9 (33%) 8 (30%)
Make vision recover to
normal
7 (26%) 6 (22%)
Make vision recover faster 17 (63%) 23 (85%)
Pain relief 4 (15%) 3 (11%)
Don’t Know 5 (18%) 0
Non Responders 1 (4%) 0
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engaging in best practice in their management can be
achieved with a simple information session. This is
important as patient knowledge of available treatment
options and treatment effects can play an integral role
to help adopting guideline recommendations in their
management.
Additional file 1: Optic Neuritis Questionnaire administered before
and after the information session. The 14 item self-administered
questionnaire before and after the information session on symptoms and
managements of optic neuritis.
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